Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Overview

USA - NASDAQ:ADAG - US0053291078 - ADR

1.74 USD
-0.15 (-7.94%)
Last: 10/22/2025, 8:14:44 PM

ADAG Key Statistics, Chart & Performance

Key Statistics
Market Cap81.97M
Revenue(TTM)103.20K
Net Income(TTM)-29889600
Shares47.11M
Float32.86M
52 Week High3.16
52 Week Low1.33
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.64
PEN/A
Fwd PEN/A
Earnings (Next)03-23 2026-03-23/amc
IPO2021-02-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ADAG short term performance overview.The bars show the price performance of ADAG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

ADAG long term performance overview.The bars show the price performance of ADAG in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 60 80

The current stock price of ADAG is 1.74 USD. In the past month the price decreased by -14.29%. In the past year, price decreased by -42.19%.

ADAGENE INC-ADR / ADAG Daily stock chart

ADAG Latest News, Press Relases and Analysis

ADAG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.59 403.98B
AMGN AMGEN INC 13.57 159.34B
GILD GILEAD SCIENCES INC 15.69 150.71B
VRTX VERTEX PHARMACEUTICALS INC 25.17 109.33B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.94B
REGN REGENERON PHARMACEUTICALS 12.81 61.98B
ARGX ARGENX SE - ADR 88.4 50.13B
INSM INSMED INC N/A 33.90B
ONC BEONE MEDICINES LTD-ADR 5.06 34.44B
BNTX BIONTECH SE-ADR N/A 25.54B
NTRA NATERA INC N/A 25.81B
BIIB BIOGEN INC 9.23 21.66B

About ADAG

Company Profile

ADAG logo image Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 138 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Company Info

ADAGENE INC-ADR

4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park

Suzhou JIANGSU 215123 CN

CEO: Peter (Peizhi) Luo

Employees: 138

ADAG Company Website

ADAG Investor Relations

Phone: 8651287773632

ADAGENE INC-ADR / ADAG FAQ

What is the stock price of ADAGENE INC-ADR today?

The current stock price of ADAG is 1.74 USD. The price decreased by -7.94% in the last trading session.


What is the ticker symbol for ADAGENE INC-ADR stock?

The exchange symbol of ADAGENE INC-ADR is ADAG and it is listed on the Nasdaq exchange.


On which exchange is ADAG stock listed?

ADAG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ADAGENE INC-ADR stock?

11 analysts have analysed ADAG and the average price target is 9.84 USD. This implies a price increase of 465.25% is expected in the next year compared to the current price of 1.74. Check the ADAGENE INC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ADAGENE INC-ADR worth?

ADAGENE INC-ADR (ADAG) has a market capitalization of 81.97M USD. This makes ADAG a Micro Cap stock.


How many employees does ADAGENE INC-ADR have?

ADAGENE INC-ADR (ADAG) currently has 138 employees.


What are the support and resistance levels for ADAGENE INC-ADR (ADAG) stock?

ADAGENE INC-ADR (ADAG) has a support level at 1.73 and a resistance level at 1.9. Check the full technical report for a detailed analysis of ADAG support and resistance levels.


Is ADAGENE INC-ADR (ADAG) expected to grow?

The Revenue of ADAGENE INC-ADR (ADAG) is expected to decline by -17.84% in the next year. Check the estimates tab for more information on the ADAG EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ADAGENE INC-ADR (ADAG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ADAGENE INC-ADR (ADAG) stock pay dividends?

ADAG does not pay a dividend.


When does ADAGENE INC-ADR (ADAG) report earnings?

ADAGENE INC-ADR (ADAG) will report earnings on 2026-03-23, after the market close.


What is the Price/Earnings (PE) ratio of ADAGENE INC-ADR (ADAG)?

ADAGENE INC-ADR (ADAG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).


What is the Short Interest ratio of ADAGENE INC-ADR (ADAG) stock?

The outstanding short interest for ADAGENE INC-ADR (ADAG) is 0.13% of its float. Check the ownership tab for more information on the ADAG short interest.


ADAG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ADAG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ADAG. ADAG may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ADAG Financial Highlights

Over the last trailing twelve months ADAG reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 10.98% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -44.94%
ROE -78.84%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%25.71%
Sales Q2Q%N/A
EPS 1Y (TTM)10.98%
Revenue 1Y (TTM)-87.35%

ADAG Forecast & Estimates

11 analysts have analysed ADAG and the average price target is 9.84 USD. This implies a price increase of 465.25% is expected in the next year compared to the current price of 1.74.

For the next year, analysts expect an EPS growth of 13.69% and a revenue growth -17.84% for ADAG


Analysts
Analysts80
Price Target9.84 (465.52%)
EPS Next Y13.69%
Revenue Next Year-17.84%

ADAG Ownership

Ownership
Inst Owners23.51%
Ins Owners2.77%
Short Float %0.13%
Short Ratio0.49